{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:59:42Z","timestamp":1791233982582,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eururo.2025.09.4144","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:07:07Z","timestamp":1759522027000},"page":"116-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial"],"prefix":"10.1016","volume":"90","author":[{"given":"Markus","family":"Graefen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1907-3982","authenticated-orcid":false,"given":"Fabian","family":"Falkenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bud\u00e4us","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Aly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Brasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"R\u00f8der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads H.","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schostak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"G\u00f6rtzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Renter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"von Amsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Haese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Heinzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Steuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.09.4144_b0005","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.09.4144_b0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2025.09.4144_b0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0020","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/iju.13535","article-title":"Local treatment for metastatic prostate cancer: a systematic review","volume":"25","author":"Tilki","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.euo.2022.06.001","article-title":"Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial","volume":"5","author":"Dai","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0030","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.09.4144_b0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.clgc.2014.01.010","article-title":"Radical prostatectomy or radiotherapy in high-risk prostate cancer: a systematic review and metaanalysis","volume":"12","author":"Petrelli","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2025.09.4144_b0040","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/pros.24089","article-title":"Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer","volume":"81","author":"Emam","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.09.4144_b0045","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9\u201310 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2025.09.4144_b0050","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2023.09.024","article-title":"Long-term prostate cancer-specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer","volume":"85","author":"Herlemann","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0055","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.euo.2018.03.002","article-title":"Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases","volume":"1","author":"Heidenreich","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0060","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.juro.2014.09.089","article-title":"Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study","volume":"193","author":"Heidenreich","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0065","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.euo.2023.09.006","article-title":"Outcomes of cytoreductive radical prostatectomy for oligometastatic prostate cancer on prostate-specific membrane antigen positron emission tomography: results of a multicenter European study","volume":"7","author":"Rajwa","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0070","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.eururo.2015.05.023","article-title":"A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation","volume":"69","author":"Sooriakumaran","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0075","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00345-019-02950-0","article-title":"Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H","volume":"38","author":"Knipper","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0080","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.3390\/curroncol30020170","article-title":"An updated systematic and comprehensive review of cytoreductive prostatectomy for metastatic prostate cancer","volume":"30","author":"Yanagisawa","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0085","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","article-title":"Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study","volume":"65","author":"Culp","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0090","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.euros.2021.05.006","article-title":"The role of cytoreductive radical prostatectomy in the treatment of newly diagnosed low-volume metastatic prostate cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) registry","volume":"29","author":"Lumen","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2025.09.4144_b0095","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nm.1944","article-title":"Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer","volume":"15","author":"Liu","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2025.09.4144_b0100","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s43018-023-00692-y","article-title":"Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping","volume":"5","author":"Warner","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.eururo.2025.09.4144_b0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2025.09.4144_b0110","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.juro.2013.08.010","article-title":"Radical prostatectomy improves and prevents age dependent progression of lower urinary tract symptoms","volume":"191","author":"Prabhu","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0115","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.euf.2017.06.016","article-title":"Does Cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study","volume":"3","author":"Steuber","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.09.4144_b0120","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.euo.2024.03.007","article-title":"A systematic review and meta-analysis of the impact of local therapies on local event suppression in metastatic hormone-sensitive prostate cancer","volume":"7","author":"Tsuboi","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0125","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00a0\u00d7\u00a02 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.09.4144_b0130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.eururo.2025.09.4144_b0135","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.eururo.2025.09.4144_b0140","series-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2023"},{"key":"10.1016\/j.eururo.2025.09.4144_b0145","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"issue":"17 Suppl","key":"10.1016\/j.eururo.2025.09.4144_b0150","article-title":"Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3 randomized trial with a 2 \u00d7 2 design","volume":"41","author":"Bossi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0155","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0160","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eururo.2024.03.018","article-title":"Prostate radiotherapy in low-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis","volume":"86","author":"Roy","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0165","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/j.1464-410X.2010.09730.x","article-title":"Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study","volume":"107","author":"Steuber","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.09.4144_b0170","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2009.12.034","article-title":"Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer","volume":"57","author":"Engel","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0175","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","article-title":"Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): an open randomised phase III trial","volume":"373","author":"Widmark","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.09.4144_b0180","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.09.4144_b0185","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.prnil.2018.10.002","article-title":"Results of phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer","volume":"7","author":"Yuh","year":"2019","journal-title":"Prostate Int"},{"key":"10.1016\/j.eururo.2025.09.4144_b0190","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.eururo.2024.08.030","article-title":"Radical prostatectomy versus stereotactic radiotherapy for clinically localised prostate cancer: results of the PACE-A randomised trial","volume":"86","author":"van As","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4144_b0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartres","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2025.09.4144_b0200","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-6215-10-14","article-title":"The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost","volume":"10","author":"Vickers","year":"2009","journal-title":"Trials"},{"key":"10.1016\/j.eururo.2025.09.4144_b0205","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.2967\/jnumed.123.265916","article-title":"Do bone scans overstage disease compared with PSMA PET at initial staging? An International multicenter retrospective study with masked independent readers","volume":"64","author":"Hope","year":"2023","journal-title":"J Nucl Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825046871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825046871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:26:39Z","timestamp":1785885999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825046871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0302283825046871"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4144","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}